Literature DB >> 16221224

ACE I/D polymorphism is associated with mortality in a cohort study of patients starting with dialysis.

Femke van der Sman-de Beer1, Claudia Verhagen, Saskia M Rombach, Peter Boorsma, Jeannette G van Manen, Johanna C Korevaar, Ruud van den Bogaard, Elisabeth W Boeschoten, Raymond T Krediet, Gerjan J Navis, Jan P Vandenbroucke, Friedo W Dekker.   

Abstract

BACKGROUND: In dialysis patients, only a few follow-up studies have addressed the relationship between the insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene and mortality, but the available data are contradictory.
METHODS: A cohort of 453 consecutive patients starting dialysis between January 1999 and January 2002 and participating in a Dutch multicenter prospective study was examined. Patients who died within 3 months after the start of dialysis were excluded. Patients were followed until date of death or censoring in November 2003.
RESULTS: The ACE II, ID, and DD genotype frequencies were 24.3% (N = 110), 50.1% (N = 227), and 25.6% (N = 116). Besides a slightly higher number of Caucasians in the DD group, all other patient characteristics of the 3 ACE groups were similar at the start of dialysis. After adjustment for age, comorbidity, and ethnic background, patients with the ID and DD genotype showed an increased hazard ratio (HR) for all-cause mortality of 1.55 (95% CI 1.00-2.42) and 2.30 (95% CI 1.41-3.75), compared to patients with the II genotype. Slightly lower HRs were found for cardiovascular mortality. All groups of primary kidney disease showed a 2- to 3-fold increased adjusted HR for DD.
CONCLUSION: The DD genotype identifies dialysis patients at an increased risk for mortality.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221224     DOI: 10.1111/j.1523-1755.2005.00681.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

Review 1.  Genetic Polymorphisms and Peritoneal Membrane Function.

Authors:  Imad Siddique; K Scott Brimble; Louise Walkin; Angela Summers; Paul Brenchley; Sarah Herrick; Peter J Margetts
Journal:  Perit Dial Int       Date:  2014-11-13       Impact factor: 1.756

Review 2.  Sudden cardiac death in chronic kidney disease: epidemiology and prevention.

Authors:  M Khaled Shamseddin; Patrick S Parfrey
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

3.  Interaction between angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on survival in hemodialyzed patients.

Authors:  István Kiss; Csaba Ambrus; Imre Kulcsár; János Szegedi; Lóránt Kerkovits; András Tislér; Zoltán Kiss
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

4.  The Effect of Angiotensin Converting Enzyme (ACE) I/D Polymorphism on Atherosclerotic Cardiovascular Disease and Cardiovascular Mortality Risk in Non-Hemodialyzed Chronic Kidney Disease: The Mediating Role of Plasma ACE Level.

Authors:  Hendri Susilo; Budi Susetyo Pikir; Mochammad Thaha; Mochamad Yusuf Alsagaff; Satriyo Dwi Suryantoro; Citrawati Dyah Kencono Wungu; Ifan Ali Wafa; Cennikon Pakpahan; Delvac Oceandy
Journal:  Genes (Basel)       Date:  2022-06-23       Impact factor: 4.141

Review 5.  Angiotensin-converting enzyme insertion/deletion polymorphism contributes high risk for chronic kidney disease in Asian male with hypertension--a meta-regression analysis of 98 observational studies.

Authors:  Chin Lin; Hsin-Yi Yang; Chia-Chao Wu; Herng-Sheng Lee; Yuh-Feng Lin; Kuo-Cheng Lu; Chi-Ming Chu; Fu-Huang Lin; Sen-Yeong Kao; Sui-Lung Su
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

6.  Survival and predictive factors of lethality in hemodialysis: D/I polymorphism of the angiotensin I-converting enzyme and of the angiotensinogen M235T genes.

Authors:  Mauro Alves; Nelson Albuquerque de Souza e Silva; Lucia Helena Alvares Salis; Basilio de Bragança Pereira; Paulo Henrique Godoy; Emília Matos do Nascimento; Jose Mario Franco Oliveira
Journal:  Arq Bras Cardiol       Date:  2014-07-29       Impact factor: 2.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.